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The following Investment Committee Paper consists of a proposal for a Leveraged Buyout on Select Medical Holdings Corp, a United States key player, operating in
different segments - Rehabilitation Hospitals, Outpatient Rehabilitation Clinics, Occupational Health Centers, and Critical Illness Recovery Hospitals. In this paper, the
group presents an investment thesis comprising of value creation strategies such as portfolio expansion, operational turnaround, and strategic acquisitions that are
incorporated in a forecasted operating model. Afterwards, a company valuation is conducted as well as an assessment of the optimal capital structure. Lastly, possible
exit options are presented, and returns are calculated.
Disclaimer:
Private Equity, LBO, Select Medical, Physical Therapy
The following Work Project was elaborated by a group a students from the Master in Finance from NOVA School of Business and Economics. We solemnly pledge that
the presented Work Project was done accordingly to the University’s Code of Honor, being entirely our own. This Investment Committee Paper was developed for
academic purposes only thus we do not take any responsibility for legal, investment or other decisions built upon this paper. The data used on the Work Project was
completely gathered from publicly available sources.
The Work Project is composed by three interdependent parts, as such, for a complete understanding of the Investment Committee Paper, please refer to “Select
Medical Holdings Corp – Investment Committee Paper” and “Select Medical Holdings Corp – Leveraged Buyout”.
This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences
DataLab, Project 22209), POR Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) and POR Norte (Social Sciences DataLab, Project
22209).
Select Medical Holdings Corp
Private Equity Buyout
January 2021 Private Equity Challenge
Prepared by:
Catarina Rocha Ferraz | 41023
Advisor:
Luís Mota Duarte
Nova School of Business and Economics | Private Equity Challenge
4



















In-depth analysis of Value Creation Strategies and Business Plan………….…..
Personal Reflection | The role of technology in the future of Healthcare …..
Page 19
Page 25
























Company Overview | Information on SEM’s Business Segments
Nova School of Business and Economics | Private Equity ChallengeSelect Medical Holdings 
SEM thrives with an adaptive business model that attracts many but different needs’ patients
5
Patients requiring occupational 
medicine/therapy consumer health 
services, focused on the health of 
America’s workforce
Source: Select Medical’s Annual Report 2019 and website, Bloomberg
Rehabilitation Hospitals Outpatient Rehabilitation Clinics Occupational Health CentersCritical Illness Recovery Hospitals
Patients that require physical, 
occupational and speech 
rehabilitation
Patients that require intensive physical 
rehabilitation care to rebuild function
Patients recovering from critical and 














68% Occupancy Rate 76% Occupancy Rate 8,719,282 Visits 12,068,865 Visits
1st Admission into one of CIRHs,
which ensures patient’s needs are met
2nd Full assessment of the patient by
specialized health care professionals
3rd Ongoing care and recovery
supported by daily physician rounds
Concentra offers occupational health
services to employers and respective
workforce, at the workplace or at a
clinic, to maintain its health and
safeguard, while reducing the overall













Net Revenue per 
Patient Day
Net Revenue per 
Patient Day
Net Revenue per 
Visit
Net Revenue per 
Visit
SEM's competitive position is affected by its ability of negotiating contracts with payors and, therefore, its prices can vary and rely on such agreements. The nature of
the firm’s industry and a highly fragmented market lead to competition between healthcare providers, giving payors significant influence and negotiating power.
However, Select Medical’s size and national presence, allow for strong bargaining power as well.
34% of Total Revenues & 101 Locations 12% of Total Revenues & 29 Locations 
19% of Total Revenues & 1740 
Locations 
30% of Total Revenues & 521 
Locations 
1st Referral to one of RHs, followed by
assessment of care needed
2nd Care team evaluation to create a
custom rehabilitative plan
3rd Treatment supported by healthcare
workers to maximize independence
1st Initial evaluation by therapist who
proposes an individual treatment plan
2nd Regularly scheduled appointments
with a clinical member
3rd Treatment supported by healthcare
workers to maximize independence
Attracting clients through 3 channels: word of mouth (based on SEM’s reputation), doctors’ referral and private and public insurance programs agreements
Nova School of Business and Economics | Private Equity ChallengeSelect Medical Holdings 
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Historical Financial Analysis | Income Statement
Acquisitions have been contributing and improving operational performance at Select Medical
Income Statement in $M 2015 2016 2017 2018 2019
Critical Illness Recovery Hospital 1 903 1 757 1 725 1 754 1 837
Rehabilitation Hospitals 444 498 509 584 671
Outpatient Rehabilitation Clinics 810 979 961 996 1 046
Concentra Occupational Health Centers 585 982 1 013 1 558 1 629
Other 1 1 157 190 272
Total Revenues 3 743 4 217 4 365 5 081 5 454
growth % 13% 4% 16% 7%
Organic Revenues 3 159 4 217 4 365 4 592 5 454
Inorganic Revenues 584 489
Cost of Services 3 268 3 665 3 735 4 341 4 641
Gross Profit 474 552 630 740 813
Gross Margin % 13% 13% 14% 15% 15%
G&A 95 107 114 121 128
D&A 105 145 160 202 213
Reported EBITDA 380 445 516 619 684
EBITDA Margin % 10% 11% 12% 12% 13%
Net Income 136 125 221 177 201





2015 2016 2017 2018 2019
Revenues per BU as % of Total Revenues




• SEM’s revenues grew at a CAGR of 9.87%.
• Major source of revenue is Critical Illness, however its
weight on total revenues has been decreasing.
• Regarding payor source, most revenues come from
Commercial Insurance (32%), followed by Medicare
(26%) and Workers’ Compensation (21%).
A
B
• Inorganic revenues: 16% and 10% of revenues are
attributed to acquisitions in 2016 (Concentra) and
2018 (U.S. HealthWorks), respectively.
B
• COS are relevant since SEM operates in a people intensive industry.
• In 2015, around half of the increase in COS resulted from the addition of Concentra, which
operated with a higher relative COS percentage to revenues than Select. The remaining increase
was due to training initiatives, which continued throughout the years, and higher staff turnover.
• In 2018, the increase resulted from the acquisition of U.S. HealthWorks (facility rent expense).
C
C
• SEM’s gross margin has been slightly increasing throughout the years, due to increasing
revenues. However, COS have been increasing as well but with a lower CAGR.
D
• The increase from 2015 to 2016, is due to Concentra
and, from 2016 to 2017, it is due to Physiotherapy.





Note: Please check Appendix II.1. for a more detailed analysis of the Income Statement. Note: in 2019, for comparison purposes, we had to undue the adoption of a new accounting standard on Leases (ASC Topic 842).
Source: Select Medical’s Annual Reports
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Historical Financial Analysis | Statement of Cash Flows
Select Medical’s Free Cash Flow has a CAGR of 191% from 2016 to 2019
Free Cash Flow In $M 2015 2016 2017 2018 2019
EBITDA 380 445 516 619 684
growth % 17% 16% 20% 11%
- Income Taxes 72 55 -18 59 64
growth % -23% -133% -422% 9%
- △NWC -113 171 124 -28 219
growth % 100% -27% -123% -882%
- CAPEX 418 157 163 239 201
growth % -62% 4% 47% -16%
FCF (cash generation) 3 61 247 349 200
growth % 2108% 303% 42% -43%
Cash Flow Statement in $M 2015 2016 2017 2018 2019
Net Income 136 125 221 177 201
+ Non-Cash Items 153 203 114 233 257
+ Changes in Net Working Capital -81 18 -97 84 -13
Cash Flow from Operating Activities 208 346 238 494 445
As % of total Revenues 6% 8% 5% 10% 8%
+ Purchases of PP&E -183 -162 -233 -167 -157
As % of total Revenues 5% 4% 5% 3% 3%
+ Net Payments for Acquisitions -1 063 -396 40 -530 -160
+ Net Payments for Marketable Securities 33 4 0 0 0
Cash Flow from Investing Activities -1 213 -554 -193 -697 -317
As % of total Revenues 32% 13% 4% 14% 6%
+ Debt-related Cash Flows 830 284 -8 574 98
+ Equity-related Cash Flows 184 8 -13 -318 -66
Cash Flow from Financing Activities 1014 292 -22 256 32








• Operating CF has been fluctuating since 2015.
• Partially attributed to oscillations in A/R and in
deferred income taxes.
A
• As a capital-intensive industry such as healthcare,
Select Medical faces slight changes when it comes
to Purchases of PP&E since 2015.
B
• Downward trend in Investing CF.
• Significant increase in 2015 and 2018 due
to acquisitions of Concentra and U.S. HealthWorks.
C
• In 2017, Income Taxes were negative due to effects
resulting from a reform considering federal
legislation on deferred tax liability.
D
• SEM’s Free Cash Flow has been increasing since
2015, except for 2019.
• Mostly due to oscillations in captions that
determine NWC and its investment.







2015 2016 2017 2018 2019
Note: Please check Appendix II.3. for a more detailed analysis of the Statement of Cash Flows. Source: Select Medical’s Annual Reports
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Market Overview | American Healthcare Industry - Segments
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
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Medical Goods Collective Services and Capital Formation
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• U.S. inpatient care market is expected to grow
at 5.8% CAGR until 2024, accounting for
17.4% of the total healthcare industry in 2019.
• This segment’s growth is restricted by the cost
of U.S. healthcare.
• U.S. outpatient care is expected to grow at
7.07% CAGR until 2024, accounting for 50.8%
of the total healthcare industry in 2024.
• The outpatient care segment is less capital
intensive when compared to others.
• U.S. long term care is expected to grow at
5.42% CAGR until 2024, accounting only 4.8%
of the total industry in 2019.
• However, it accelerated more than any other





















• U.S. medical goods market is expected to grow
at 6.07% CAGR until 2024.
• This segment’s weight in the healthcare
industry is expected to decrease throughout
the years, being around 11.9% in 2024.
• This segment is expected to grow at 6.42%
CAGR until 2024.
• This segment’s weight in total healthcare
expenditures will slightly decrease and
stabilize at 16.2% in 2024.
Inpatient and Outpatient Care are the most relevant segments in the healthcare industry
Main takeaways: 
Source: Marketline “Healthcare providers in the United States”, Select Medical’s reports
Outpatient care is the segment expected to
grow at a faster pace. Also, it is expected that
this segment’s weight increases until 2024.
Inpatient care’s weight on the entire
healthcare industry has increased however,
from 2018 until 2024, it is expected to decline.
The long-term care and medical goods
segments have been constantly decreasing
















545 571 574 596
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Investment Thesis
Select Medical’s background and experience allows for superior competitive position
Deal Rationale
Value Creation Strategies
• Select Medical Holdings has the ability to strengthen
its leadership position by adapting to the new context
brought by the pandemic.
• Namely, by diversifying its services portfolio and
offer better and competitive solutions.
• Select Medical can explore new opportunities in the
telemedicine and behavioral health industries
concerning outpatient and occupational therapy,
offering alternatives to patients who are in need and
expand its services’ portfolio, creating a new stream of
revenue for the firm.
• Due to the high level of fragmentation of the
healthcare industry, SEM can acquire and
incorporate strategic players in the market,
improving its competitive positioning and
assure growth.
• The company has a strong track record and
experience in successfully completing and
integrating acquisitions.
• Select Medical can improve its operations
management.
• According to the company’s annual report,
operating performance can be improved at the
acquisitions level, for example, by imposing best
management practices and by realizing
efficiencies, as the activities and management
would be centralized.
• Furthermore, the firm is well positioned to
improve its free cash flow generation and
management.
Operational TurnaroundBolt-on AcquisitionsPortfolio Expansion
• The company portraits
willingness to expand and
acquire new companies in
the future, in order to
consolidate its position.
• Select Medical has proven its
ability regarding the
selection and target
integration of the acquired
firms.
• The success of Select Medical is
based on several competitive
strengths, including the leading
position in each business segments.
• The segments have all been growing
in the past years and present
prospects of profitable growth
mainly due to the company’s strong
reputation and national presence.
• The company presents a track record of
increasing revenues and EBITDA margin.
• Healthy FCF generation which has been
positive and overall increasing
throughout the years and is expected to
continue to deliver such values.
• The company has a leverageable balance
sheet due to a strong asset base (growing
at a CAGR of 9.37%) and a low and
decreasing CAPEX as % of sales.
• Select Medical Holdings is
backed-up by a strong
management team with years
of experience in this industry as
well as in the company.
• Most executives have been on
the firm for several years and
have proven their ability on
leading the company.
Leading market position1 432 Good financial performance Skilled management team Acquisitions experience
Source: Select Medical’s Annual Reports
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Value Creation Strategies | Portfolio Expansion
Through an expansion of the services SEM provides, it can strengthen and improve its leading position
Select Medical Holdings 
Select Medical has a Market leading position which 
can be leveraged and consolidated by expanding
and diversifying its services’ portfolio
Telemedicine
STATUS QUO PORTFOLIO EXPANSION RATIONALE OBJECTIVES
Select Medical should implement the following 
services in its Outpatient/Concentra segments:
Behavioral Health
With these two segments within the services
offering, Select Medical will consolidate its
clients base and attract new clients, which will
lead to a rapid increase in revenues and to a
differentiating advantage among its peers.
Growth of revenues from existing clients
within the new services.
1
Complete and diversify services panoply that
are offered by Select Medical.
2
Attract new clients, creating new revenue
streams.
3
Improvement of competitive advantages
such as the leadership in Outpatient/Concentra
segment.
Within the Outpatient Rehabilitation and Concentra
segments, the following services are provided:
Physical 
Therapy*






















*services that may be adapted to telemedicine





• Higher revenue growth.
• Broader clients base.
• Lower operating costs.
• Consolidation of Select Medical as market leader
in outpatient and occupational segments.
• Higher revenue growth.
• Broader clients base.
• New revenue stream that complements services
already provided.
Acquire adequate software (i.e. app) to be able to:
• conduct online consultations.
• transfer of health history and/or medical records1.
• monitor patients’ health and medical data1.





















In states like Arizona, Colorado, North and South Carolina, SEM
will invest:
• In behavioral healthcare professionals.
• In equipment for specific segments of behavioral health (i.e. autism).




Note: Please check Appendix III.1. and III.2. for detailed analysis of Telemedicine and Behavioral Health strategies.
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Value Creation Strategies | Bolt-on Acquisitions
Select Medical Holdings 
STATUS QUO RATIONALE OBJECTIVES
EXPECTED RESULTSEXECUTION
Bolt-on acquisitions strategy allows for value creation and market consolidation
SEM has successfully been acquiring attractive
targets to consolidate its leadership position as
one of the largest health care providers in the
segments that it operates, based on the number of
facilities and revenues.
• The company’s selective M&A policy aligned
with well-defined acquisition criteria have
been proved successful so far.
• The highly fragmented market of
Outpatient and Concentra offer opportunities
for consolidation and strengthening of Select
Medical’s competitive position.
• The Outpatient segment is growing and has
been little affected by economic downturns.
• The more fragmented the market is, the lower
the negotiating leverage of healthcare
providers. Therefore, consolidation helps SEM
become larger with fewer competitors, which
increases its pricing power over private
insurance companies.
Strengthen the competitive position and expand
the portfolio, increase revenues, reduce
operational and fixed costs (economies of scale),
and acquire a stronger ability to navigate the
uncertainty surrounding the future of healthcare.
1 Value creation
• Acquire companies with strong cash flows and
revenue growth in order to improve Select
Medical’s revenues through cross-selling and
enlargement of the customer base.
• Allow Select Medical to continue to provide
care for its patients after being discharged
from critical care.
• Improve operating margins through cost
synergies obtained with the acquisitions.
Consolidate market position
• Obtain significant position in the
Outpatient segment, which is growing faster
than any other segment.
• Expand the portfolio of segments in which
Select Medical is present.
• Become an even more significant national
player in the healthcare sector.
• Acquire two pre-selected targets, which are located across the U.S..
• Formulating and executing an integration plan for the acquired 
companies to benefit from cost synergies and larger client base. 
• Additional inorganic EBITDA between 2020 and 2025 of more than 
$300M.
• Expansion of portfolio and cost related synergies. 
11
Competitive position & Portfolio expansion
• Market divisions across the U.S. provide
opportunities for M&A in order to increase
SEM’s market share.
• Acquiring companies with expertise in other
health care segments allows rapid entrance in
new profitable segments.
Revenues growth
• Integrating new companies improves organic
sales growth in the following years after
acquisition.
Economies of scale
• SEM’s fixed costs are large and horizontal
expansion can spread those costs across a
greater volume of patients.
2
Source: Company’s annual reports and website and Marketline “Healthcare providers in the United States” 
Drive growth of operating margins towards peers’
values through efficiency enhancements measures.
2019 2020 2025
2015 2016 2017 2018 2019
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Value Creation Strategies | Operational Improvement
Enhanced profitability through the implementation of an ERP system and use of innovative technologies  
Select Medical Holdings 











• Cease operations in less efficient facilities and
in states with lower reimbursement rates.
• Cost cutting and efficiency gains through the
implementation of better operating systems.
• Use of innovative technologies in the facilities.
SEM’ management team has been centralizing key
administrative services in order to improve operating
efficiency and control costs. Cease facilities
• Decrease the number of less efficient clinics in
states with lower reimbursement rates (Florida
and Texas which also have a higher percentage
of uninsured population) and also due to the
introduction of telemedicine.
• Assess states with higher number of outpatient clinics and lower
reimbursement rates to cease less efficient facilities.
• Implement ERP in current and acquired facilities, increasing
productivity and efficiency and providing management with
better tools to assess operating performance.
• Implement advanced robotics in inpatient rehabilitation clinics.
• Profitability margins closer to peers’, becoming more competitive.
• Maximized efficiency throughout facilities and faster incorporation of
acquired companies or facilities.
• Improvement of service quality through better management services
which allow physicians to provide better care.
• Development of provided care through the use of innovative technologies.
1 Increase operating margins
2 Increase revenues through new patients
• The ERP implementation allows for better
management and providing better patient care,
increasing quality and attracting patients.
• Innovative technologies contribute to a faster
rehabilitation and patients’ engagement,
increasing the quality of the service provided.
Take an insightful look into the company’s operating
performance and take advantage of technology to
improve SEM’s performance.
Innovative technologies
• Provide first-class service and care to assist
and contribute to patients’ recovery.
Implementation of ERP system
• Through ERP, Select Medical will have a more
detailed and wholesome knowledge of the
company’s financial and operating performance.
12






Note: Please check Appendix III.4 for detailed analysis of Operational Improvement. Source: Select Medical’s Annual Reports and website
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Business Plan | Overview of Main Drivers
With strategic acquisitions and costs improvement, SEM is set for a high growth path in the next 6 years
Select Medical Holdings 











3 Net Working Capital
Select Medical will be acquiring two other small
strategic companies. These will allow to:
• Add revenues of $953M at exit.
• Enter the respiratory services and post-
acute care segments, which both yield high
revenues.
• Increase SEM’s geographical presence.
Main drivers of SEM’s organic growth:
• Growth of SEM’s on-facility services, and
telemedicine services especially in Outpatient
and Concentra segments, almost in line with
each segment’s market growth.
• The most relevant segments within the organic
revenues are Concentra Occupational Health
Centers and Critical Illness Recovery Hospital.
• COS are expected to grow at a CAGR1 of 6.90%.
• SEM will benefit from synergies due to acquisitions (we
expect supplies expense to decelerate its growth by
1.25% per year from one year after the first acquisition
onwards), and the operational turnaround will allow it
to close the less profitable facilities.
• However, portfolio expansion strategy will not allow
COS to slow down as much since more healthcare
professionals will be employed.
Even though it remains constant at 3% of
Revenues, Maintenance CAPEX faces an increase
of $113M from 2019 to 2025 due to strategies
and equipment2 to achieve target revenues.
The Expansion CAPEX is stable as percentage of
total revenues. However, in 2020 and 2022 it will
significantly increase due to acquisitions that
will contribute with $88M in EBITDA at exit, in
2025. Acquisitions will be financed using 50% of
CAPEX facility and 50% of cash.
Net Working Capital is constantly increasing
during the entire investment period due to a
general increase in all current assets, especially
cash and cash equivalents.
% of RevenuesIn $M
2- Includes Equipment of SEM, Viemed and Diversicare
5 454 5 749 6 075 6 459
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2019 2020 2021 2022 2023 2024 2025 2026
Maintenance CAPEX Net Working Capital
2
1
1- From 2020 to 2025
G&A: It is expected to increase in 2020 due to investment
in ERP system. However, from 2021 to 2025, it will
decelerate its growth fulfilling cost-efficiencies.
D&A: its YoY growth is fairly stable however, in 2020 and
2022 it increases due to the acquisitions of Viemed (6%)
and Diversicare (11%), accordingly.
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Exit & Returns | Capital Structure
Select Medical Holdings 
Total leverage of 5.5x EBITDA and an equity contribution of 9.8x EBITDA for SEM’s acquisition
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Uses of Funds
• Total uses of funds, totalling $10,446m, are destined
to pay for EV of $10,134m and the remaining
amount is for financing fees and other fees and
expenses related to the transaction.
• Enterprise Value is based on a EV/EBITDA multiple
of 14.81x estimated in the valuation section.
Sources of Funds
• Total uses of funds are sourced from an equity
contribution of 9.8x EBITDA ($6,681m) and
leverage of 5.5x EBITDA ($3 765m).
• For the debt portion of the sources, there are three
tranches of senior debt and mezzanine debt. All of
the mentioned are contracted in U.S. dollars and
non-amortizing for tranches B and C and mezzanine.
• The equity contribution is composed of a fixed
return instrument of $6,481m and ordinary equity
of $190m.
• Top management will hold $10m worth of shares
(sweet equity), which is twice their combined annual
compensation, and also $45m of FRI and $1m of
ordinary equity, in order to align interests.
Other
• A CAPEX Facility of $236m will be used to partially
finance the planned acquisitions throughout the
investment period.
• Three potential capital structures were
analyzed so as to compare returns at exit
Capital structure 1 is the preferred as
Capital Structure 2 delivers a slightly lower
money multiple at exit and the leverage
multiple is the same.
• Capital Structure 3 requires the lowest
amount of debt, and yields the lowest MM.
Note: Please check Appendix IV.4, IV.5, IV.6 for detailed capital structures in different scenarios and IV.7 for detailed financing structures. 
CommentsAmount % xEBITDA Pricing Amount %
Term Loan A - - - L + 375 bps Equity Purchase $7 025 67.3%
Term Loan B $2 053 19.7% 3.0x L + 400 bps Repay Existing Debt $3 109 29.8%
Term Loan C $1 027 9.8% 1.5x Financing Fees $210 2.0%
Mezzanine $684 6.6% 1.0x Other Fees and Expenses $101 1.0%
PIK Element 600 bps
Cash Element L + 675 bps
Institutional Strip
PE Fund
Fixed Return Inst. $6 435 61.6% 9.4x 1250 bps
Institutional Ords $189 1.8% 0.3x
Total $6 624 63.4% 9.7x
Management
Fixed Return Inst. $46 0.4% 0.1x 1250 bps
Institutional Ords $1 0.0% 0.0x
Total $10 0.1% 0.0x
Sweet Equity $57 0.5% 0.1x
Total Sources $10 446 100% 15.3x Total Uses $10 446 100%
Instrument Structure 1 Structure 2 Structure 3
Senior Tranche A - $856 -
Senior Tranche B $2 053 $1 027 $1 711
Senior Tranche C $1 027 $1 027 $1 027
Mezzanine $684 $856 $684
Equity Contribution $6 681 $6 681 $7 024
Leverage 5.5x 5.5x 5.0x
MM at Exit 3.03x 3.02x 2.95x
0 5 000 10 000 15 000 20 000 25 000
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Exit & Returns | Entry Valuation
Select Medical Holdings 
Through the football field analysis with several methodologies, a 14.81x EV/EBITDA multiple was achieved
15
Comments
• Sources: Bloomberg and Reuters.
• The minimum value for the multiple was 11.39x whilst
the maximum was 27.08x, suggesting a big gap
between valuations.























• Precedent transactions were selected from Reuters
industry sector.
• As seen in the previous methodology, there is also a
large interval between minimum and maximum
multiples, 5.70x to 24.99x.
• Overall, multiples of comparable companies have been
increasing throughout the years however, 2018, seemed
to be the year with the highest multiples.
• The minimum multiple was 8.49x (2016) and the
maximum was 27.54x (2018).
• The share prices 1 day, 1 week and also 1 month prior to
acquisition (of the same companies as in precedent
transactions) were analyzed.
• The premium was applied to SEM’s share price prior
to acquisition.
• For the DCF, WACC was estimated based on the
company’s latest bond issues and recent information.
The terminal growth rate ranged from 1.0% to 1.5%.




Note: Please check Appendix IV.1, IV.2 and IV.3 for detailed methodology analysis.
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Exit & Returns | Returns Breakdown
Select Medical Holdings 
RETURNS BREAKDOWN
Select Medical’s strong margin evolution and revenue growth will drive a Money Multiple of 3.03x
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• The Revenue Growth is the most
important return driver in the
Investment Case, contributing with
0.86x in terms of multiples.
• This is obtained due to the business
strategy of implementing new
revenue streams and of
accomplishing new acquisitions.
Revenue Growth Margin Evolution Deleveraging
Entry & Exit Fees
Multiple Arbitrage
• The Margin Evolution is the
second most important return
driver in the Investment Case,
contributing with 0.82x in terms of
multiples.
• This is obtained due to the high
revenue growth throughout the
investment period and due to the
efficiency gains predicted in the
business plan.
• The Deleveraging is the third most
important return driver in the
Investment Case, contributing with
0.23x in terms of multiples.
• This is obtained mostly due to the
demanding and well-established
debt repayment schedule but also
due to the great performance that
is expected from Select Medical.
• The Multiple Arbitrage is expected to
have a null impact on the returns as
the U.S. economy will face many
challenges in the near future.
• The Entry & Exit Fees will play a
















Entry Equity Entry Fee Revenue Growth Margin Evolution Multiple Arbitrage Deleveraging Exit Fees Exit Equity
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Exit Strategy | Exit Options
Select Medical Holdings 
Strategic Sale
Strategic sale is the most favorable exit option for the Private Equity Fund
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• Healthcare is highly fragmented
in the U.S. and there are
significant consolidation efforts
in the market, leading to several
interested buyers and a strong
competition.
• There are larger healthcare
companies with resources to
acquire SEM and gain synergies.
• Despite the crisis created by the
ongoing pandemic, there has
been M&A activity in the
healthcare industry among PE
funds.
• Private Equity funds had around
$2 trillion of dry-powder as of
July 2020.
• An IPO would allow Select
Medical to have access to a
larger market when comparing
with the remaining exit options.
• Considering the size of the
company, it is a good potential
candidate for this exit strategy.
• Potential buyers might only be
interested in some segments of
the company.
• Some business segments are
growing at a faster rate than
others.
• Depending on the situation, the
transaction might be a slow
process.
• There is the possibility that
investors are in both the buyers’
and seller’s funds thus, not
getting liquidity and end up
investing in the same company.
• Other PE firms may believe the
efficiencies have been explored
to their maximum.
• This strategy relies on the
current capital market
conditions and is generally more
expensive.
• With the current COVID-19 crisis,
there is still uncertainty
regarding forecasts and
prospects for the markets in
2024, increasing risk.
• This exit strategy leads to the
loss of synergies created
throughout the investment
period.
• Might lead to longer process
since it would require several
buyers.
Source: PwC
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Exit Strategy | Key Due Diligence Areas
Select Medical Holdings 
Area
Important areas such as Commercial and Financial must be further explored for a successful transaction 
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• How dependent is the market growth from macroeconomic
conditions
• Examination of genuine strength of significant patterns during
the next 5 years for each segment where SEM operates
• Economic crisis materially impacting the forecasts,
affecting revenues
• Overestimation of positive outlook in target markets
• Future market trends that SEM is not capable of
supplying
• Identify the type of patients that most utilize SEM’s services
• Evaluate if there are patients that were lost in the recent years
and why it happened
• High dependency on some types of patients
• Considerable number of unsatisfied patients
• Thoroughly analyze the acquisition targets (specially margins,
growth prospects and synergies)
• Inability to follow the acquisition strategy due to
difficult integration and/or unrealistic synergies
• Detailed analysis of competitors per service and location
• Compare SEM’s competitive advantages with the competitors’
• Inability to outperform the market
• Competitors being able to replicate SEM’s business
model and service quality
• Evaluation of the efficiencies and cost reductions obtained with
the implementation of ERP system
• ERP system implementation takes a long time and
generates more costs than benefits on the ST.
• Explore in detail and question some of SEM’s current suppliers
• Assess post-integration synergies after targeted acquisitions
• High dependence on a few suppliers can difficult
the operational turnaround strategy
• Perform an in-depth financial statement analysis (revenue and
cash-flow generation, debt valuation assumptions, evaluate
Goodwill and PP&E to assess any necessary impairments)
• Accounting frauds (overstating revenues,
unrecorded expenses, misstatement of assets and
liabilities)
• Evaluate facilities’ utilization rates & capacity to foster growth
• Compare the leasing of facilities strategy with their ownership
• It is difficult to increase the nr. of services offered at
current facilities if they are at maximum capacity
• Verify compliance with environmental policies, assess insurance
coverage, and any tax-related case pending with tax authorities
• Lack of proactive ESG actions, inappropriate
insurance coverage
• Appraisal of pending pension plan payments • Large expected losses due to future settlements
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Value Creation Strategies | Bolt-on Acquisitions
Select Medical Holdings 
• Founded in 2006 and headquartered in Lafayette, Louisiana. The company
employs 418 people.
• Viemed is a high-level service provider of equipment and home
therapy to serve patients with various respiratory diseases in 31 states.
Viemed Healthcare, Inc.
Both Viemed and Diversicare allow Select Medical to expand its care line for its patients


























• Revenue growth in the Outpatient segment: SEM would be able to cross-
sell Viemed’s products to its existing patients and vice-versa.
• Enter respiratory equipment provider business segment.
• Timely opportunity for respiratory products in the amidst of Covid-19.
• Profitability of home respiratory service business.
• Expand SEM’s geographical presence.
• Administrative and supplies costs savings: SEM would be able to reduce
the number of employees and use Viemed as a supplier for respiratory








• Founded in the early 1980s and headquartered in Brentwood,
Tennessee, employing 6,800 people.
• Diversicare provides post-acute care services and assisted living in 9
states, operating 62 facilities.
• Revenue growth in the Outpatient and Inpatient segments: SEM
would be able to cross-sell and up-sell Diversicare services to its existing
patients and vice-versa, being able to continue to offer care post-
rehabilitation.
• Assisted living would cease an opportunity for SEM: growing market
due to increase in geriatric population.
• Profitability of post-acute care segment, which complements SEM’s.
• Administrative and supplies costs savings: SEM would be able to
reduce the number of employees and have stronger bargaining power.




Note: Please check Appendix III.3 for detailed analysis of Viemed and Diversicare.
EBITDA FY19 ($M)
Entry multiple1




























1 -Based on relative valuation methods
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Business Plan | Financials Forecast - Revenues
Select Medical’s revenues are forecasted to grow at a CAGR of 8.59% from 2020 to 2025



















CIRH is Select Medical’s largest segment
despite the lower CAGR. It is expected to
grow due to COVID-19 admissions and
throughout the investment period, due to
aging population and other market trends.
RH is expected to grow throughout the
investment period due to the acquisition
of leading technology in the rehabilitation
field, bettering provided care and
attracting people with rehabilitation needs.
Revenue split 2020 versus 2025
Revenues (in $M) 2019 2020F 2021F 2022F 2023F 2024F 2025F 2026F
Critical Illness Recovery 
Hospital
1 837 2 047 2 163 2 283 2 415 2 557 2 702 2 857
Rehabilitation Hospital 671 740 755 791 847 916 984 1 049
Outpatient Rehabilitation 
Clinics
1 046 1 056 1 095 1 160 1 230 1 318 1 397 1 474
Concentra Occupational
Health Centers
1 629 1 620 1 760 1 903 2 060 2 227 2 406 2 606
Other 272 286 303 321 343 366 391 417
M&A Revenues 0 100 124 710 777 861 953 1 061
Total Revenues 5 454 5 849 6 199 7 169 7 672 8 246 8 832 9 464
Revenue growth % 7% 7% 6% 16% 7% 7% 7% 7%
Revenue contribution per strategy
In $M
2020 2021 2022 2023 2024 2025 2026
CIRH 11% 6% 6% 6% 6% 6% 6%
RH 10% 2% 5% 7% 8% 7% 7%
ORC 1% 4% 6% 6% 7% 6% 6%
COHC -1% 9% 8% 8% 8% 8% 8%
OT 5% 6% 6% 7% 7% 7% 7%
M&A 0% 24% 471% 9% 11% 11% 11%






























2020F CIRH RH OR C OT M&A 2025F
1- From 2020 to 2025
ORC will be the target of several value
creation strategies. Also, due to
improvements in technology, the shift from
inpatient to outpatient is driving growth in
this segment.
COHC’s revenues are expected to decrease in
2020 due to COVID-19. However, people
returning to work and through the strategies
implemented, this segment is expected to
grow according to market trends.
Comments
Expenses (in $M) 2019 2020F 2021F 2022F 2023F 2024F 2025F 2026F
Gross Profit 813 941 1 092 1 363 1 538 1 762 1 980 2 224
% margin 15% 16% 18% 19% 20% 21% 22% 23%
General and Administrative 128 224 239 294 324 360 402 451
Other operating expenses 0 3 4 68 72 77 83 89
R&D 0 1 1 1 1 1 1 1
Organic EBITDA 684 699 829 948 1 080 1 247 1 407 1 581
% growth 11% 2% 19% 14% 14% 16% 13% 12%
Inorganic EBITDA 15 19 53 61 76 88 103
Total EBITDA 684 713 848 1 000 1 140 1 324 1 495 1 683
% margin 13% 12% 14% 14% 15% 16% 17% 18%
% growth 11% 4% 19% 18% 14% 16% 13% 13%
D&A 213 225 238 263 281 301 321 343
Nova School of Business and Economics | Private Equity Challenge
Business Plan| Financials Forecast - EBITDA
EBITDA margin improvements arise from new offered services and acquisition synergies




1- From 2020 to 2025
15.03%
16.05% Gross margin improvements will arise
from:
• Revenue increase in the Rehabilitation
and Outpatient segments due to the
strategic acquisitions, portfolio
expansion, demographic trends, and
acquisition of robotics.
• Deceleration of Cost of Sales growth due
to implementation of operational
turnaround strategy, and strategic
acquisitions that provide economies of
scale gains and stronger bargaining
power towards suppliers.
• General and Administrative expenses will
increase from 2% of Revenues in 2019 to 4% in
2020 due to the implementation costs of the
ERP system. Nevertheless, throughout the
investment period, General and Administrative
expenses will increase at a slower pace as
revenues grow and cost efficiencies emerge.
• D&A expenses as percentage of revenues are
expected to remain somewhat constant
throughout the investment period. Nevertheless,
since Select Medical is acquiring other
companies that have a lot of facilities, opening
new facilities, and investing in robotics, D&A is
expected to increase relative to historical values.
Organic EBITDA growth comes from:
• Strong revenue growth.
• Cost efficiencies achieved at the
operational level.
• Higher gross margins.
Inorganic EBITDA growth derives from
the acquisition of two prosperous
companies in 2020 and 2022, which will
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Business Plan | Financials Forecast – Free Cash Flow
EBITDA and FCF generation are expected to have a strong growth throughout the investment period
Select Medical Holdings 
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Comments
Cumulative Free Cash Flow
CAGR1








Strong EBITDA growth with a CAGR of
15.95% achieved through strong organic
growth: business expansion, operational
improvements and bolt-on acquisitions.
1
2 Maintenance CAPEX is predicted to reach
c. $296M by 2025 and includes
maintenance expenditures attributed to
both acquisitions.
3 Expansion CAPEX peaks in 2020 due to the
acquisition of Viemed, portfolio
expansion into telemedicine and behavioral
health and the acquisition of advanced
robotics. In 2022 the peak is due to the
acquisition of Diversicare.
4
NWC is expected to increase throughout
the investment period since current assets
grow faster than current liabilities, especially
inventories since the acquired companies
have inventories .
5 FCF (excl. acquisitions) is solid despite
some fluctuations in growth. It grows at a
5.62% CAGR. In 2026, however, the NWC
decreases due to a huge cash outflow to
repay term loan B.
Free Cash Flow (in $M) 2019 2020F 2021F 2022F 2023F 2024F 2025F 2026F
EBITDA 684 713 848 1 000 1 140 1 324 1 495 1 683
Adjustments:
Income Taxes -64 -34 -57 -80 -101 -132 -160 -185
Maintenance CAPEX -183 -196 -208 -240 -257 -277 -296 -317
Expansion CAPEX -19 -204 -64 -203 -92 -105 -107 -116
Increase in Net Working   
Capital
0 -198 -368 -392 -421 -541 -664 1 204
Free Cash Flow 419 81 152 85 269 270 268 2 270
growth % -81% 86% -44% 215% 0% -1% 746%
Free Cash Flow (excl. 
acquisitions)
419 286 216 288 361 375 376 2 386
growth % -32% -24% 33% 25% 4% 0% 535%
Cummulative Cash Flow (excluding acquisitions)
Cummulative Cash Flow
26.96%
2019 2020F 2021F 2022F 2023F 2024F 2025F 2026F





Income Taxes Increase in Net Working Capital
CAPEX EBITDA
Free Cash Flow
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Business Plan | EBITDA Bridge 
EBITDA growth is expected to come mostly from EBITDA margin growth and organic revenues
Select Medical Holdings 
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EBITDA Bridge (in $M)
• The expected EBITDA
for 2020 is c. $713M,
which translates into
an increase from 2019





segments and also to
the acquisition of
Viemed in 2020.
• Viemed will be acquired in
2020 for EV/EBITDA of 8.72x.
• Viemed will strengthen SEM’s
position in the outpatient care
segment, which will receive
most of the investment through
the portfolio expansion
strategy.
• Viemed is expected to obtain
an EBITDA of $15M by the
end of 2020.
• 50% financed by CAPEX facility
and the remaining with cash.
• Diversicare is expected to be
acquired in 2022 for
EV/EBITDA of 8.20x.
• Diversicare will strengthen
the company’s national
position in the inpatient and
outpatient segments.
• Diversicare is expected to
obtain an EBITDA of $27M
by the end of 2022.
• 50% financed by CAPEX
facility and the remaining with
cash.
• The major contribution
to EBITDA is achieved
by the EBITDA margin
growth between 2020
to 2025.




• This includes the EBITDA
margin growth of the
bolt-on acquisitions.
• The forecasted EBITDA
in 2025 of $1,495M is

















Note: Please check Appendix IV.9 for a sensitivity analysis performed on Revenues growth and EBITDA margin growth.
Individual Reflection | The role of technology in the future of Healthcare 
Technology is expected to continue to reduce costs and improve healthcare quality
Select Medical Holdings Nova School of Business and Economics | Private Equity Challenge
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The role of technology
• Technology will inevitably play a central role in the future of healthcare as the shift of focus moves from responding to illnesses to supporting well-being
and therefore avoid illnesses. The population is also becoming more concerned about their own health and health habits, so it is expected that provision of
healthcare will be even more centered on the consumer rather than on the care provider institutions.
• Even though technology will be very important to conduct diagnostics, medical staff will still be very much needed to review those and to maintain the human
interaction with patients, which is essential to reassure them and make sure they follow the recommended treatments.
Artificial Intelligence
• Artificial Intelligence technology
has the capability to acquire,
collect, and organize accurate
medical images of a patient’s
health history and scans.
• AI is playing an important part in:
- Delivering precise diagnostics
through quantitative imaging - it
aids healthcare professionals to find
the best treatment based on data.
- Optimizing operations: optimize
monetary transactions, fill
prescriptions, make appointments
and process bills, therefore
increasing workforce productivity.
- Improving patient experience: It
helps prioritize complex cases.
- Creating new drugs much faster
and accurately than humans using
databases of molecular structures.
Healthcare trackers, wearables and 
sensors 
Telemedicine 
• Patients can have a more active
role in their care if they have easy
access to information about their
own health. Devices such as
wearables are designed to help
them do that.
• These devices can perform DIY
blood tests, record temperatures
and heartbeats. Thus, patients can
be pro-active, making small shifts
on their behaviors to prevent
illnesses like heart stroke or
diabetes.
• Sensors on wearable devices can
also keep track of patients’ health
and develop algorithms to
determine treatment
recommendations in case there
is an already diagnosed serious
disease.
• The use of telemedicine
drastically increased during the
COVID-19 pandemic: around 42%
of Americans have used
telemedicine during this period
so far.
• Even though this happened
partially due to higher
reimbursements and easing of
restrictions, it is expected that
even after the pandemic is over,
people are still going to
demand getting some services
at home, now that they have
realized it is possible and more
convenient.
• Telemedicine has many benefits
such as saving the travelling time
and costs for the doctors and
their patients, and less crowded
clinics and waiting rooms.
Robotics 
• Some of the uses for robot
devices are:
- Execute high precision,
minimally invasive procedures.
- Monitor the vital signs of
patients and notify doctors when
their intervention is needed.
- Perform simple task like taking
blood samples.
- Keep company to help alleviate
loneliness, treat mental health
issues and even help children with
chronic illnesses.
- Exoskeleton robotic structures can
substitute muscle power when
needed, which can aid disabled
patients regain a sense of motion
and help nurses lift heavy
patients.
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